Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Start Investors The Share Analysts following Egetis

Analysts following Egetis

DNB Carnegie: Arvid Necander & Erik Hultgård

Handelsbanken: Suzanna Queckbörner & Mattias Häggblom

Pareto Securities: Chien-Hsun Lee

Redeye: Fredrik Thor

Stifel: Oscar Haffen Lamm

Van Lanschot Kempen: Chiara Montironi

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]